Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2007

BioWa Licenses Antibody Platform to Takeda

  • Takeda Pharmaceutical has gained access to BioWa’s Potelligent® Technology platform for the development of antibody-dependent cellular cytotoxicity-enhanced (ADCC) antibodies.

    The agreement grants Takeda nonexclusive rights to research, develop, manufacture, and commercialize antibodies based on this tool for an undisclosed number of targets. In return, BioWa will receive an upfront payment, license fees, development milestones, and royalties.

    Potelligent Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, according to BioWa. Potelligent Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »